Nutcracker Therapeutics bet that personalized RNA medicine needed a smaller factory. It built one around disposable biochips, sold its know-how to drug developers, and ended up inside a larger cancer company.
Code Biotherapeutics is trying to turn DNA into the FedEx network for genetic medicine. Its modular 3DNA scaffold promises bigger payloads, precise addresses and repeat delivery - but the public evidence is still preclinical.